Clinical trials: IV Access
Melanoma
Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
This is a single arm open label, multicenter, non randomized, access study of trametinib for subjects with histologically confirmed cutaneous melanoma with a BRAF V600E/K positive mutation that is either advanced unresectable…
- Trial name
- NCT02416232
- Testing
- Trametinib, Dabrafenib
- Where
- 46 sites in France
- Sponsor
- GlaxoSmithKline
Vascular Access Complication
AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)
The study will test a hypothesis that the AccuCath™ System will have a higher rate of successful first attempt peripheral intravenous (PIV) placement, higher completion of therapy, fewer complications, longer dwell times, and…
- Trial name
- NCT01937195
- Testing
- AccuCath Intravenous Catheter System
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- C. R. Bard
Airway Control
Rapid Sequence Intubation Drug Delivery Using Intraosseous and IV Access in Pediatric Patients Observational Study
This study will evaluate using intraosseous vascular access and intravenous vascular access to give pediatric patients the necessary medications to perform rapid sequence intubation, for patients with airway difficulties.
- Trial name
- NCT01634867
- Where
- United States
- Sponsor
- Vidacare Corporation
GBM, Glioblastoma Multiforme
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
The study is an open-label expanded access study for patients for whom vaccine was manufactured during the Northwest Biotherapeutics' 020221 DCVax-L for GBM screening process, but who subsequently failed to meet specific…
- Trial name
- DCVax-L EAP (NCT02146066)
- Testing
- DCVax-L
- Where
- 27 sites in United States
- Sponsor
- Northwest Biotherapeutics
Non-small Cell Lung Cancer
Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)
This is an expanded access protocol designed to make Lucanix® available to subjects with advanced non-small cell lung cancer (NSCLC) who are not eligible for the Phase III Protocol, NR001-03.
- Trial name
- NCT01279798
- Testing
- Lucanix® (belagenpumatucel-L)
- Where
- United States
- Sponsor
- NovaRx Corporation
Difficult-to-access Veins for Intravenous Cannulation
Veinplicity for Improved Venous Access: The VIVA Trial
This study will assess the safety and effectiveness of the Veinplicity device to improve the visualization and palpability of difficult-to-access veins for intravenous cannulation.
- Trial name
- NCT03752632
- Testing
- Veinplicity with tourniquet, Tourniquet
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Physeon GmbH
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
IFx-Hu2.0 Expanded Access Program
Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients (greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma, advanced Merkel cell carcinoma (MCC), or…
- Conditions
- Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT04853602
- Testing
- IFx-Hu2.0
- Sponsor
- TuHURA Biosciences, Inc.
Intravenous Access According to Instructions For Use
Study Comparing the Handling of Two Peripheral IV Catheter Systems
A peripheral intravenous catheter is the most commonly used vascular access device in medicine. Primary objective is to compare insertion and handling of two peripheral intravenous catheters in clinical routine.
- Trial name
- NCT02213965
- Testing
- Peripheral IV catheter
- Where
- 2 sites in Germany
- Volunteers
- 2,340 people
- Sponsor
- B. Braun Melsungen AG
Patients in Need for Intravenous Access
Evaluation of Introcan Safety 3 Closed IV Catheter
Incidence and time of occurrence of blood leakage with the closed intravascular catheter Introcan Safety 3 in comparison to Introcan Safety
- Trial name
- NCT02197013
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- B. Braun Melsungen AG
Peripheral Venous Catheterization, Difficult Intravenous Access
TruVascular Access - Ultrasound-Guided Vascular Access Study
TruVascular Access - TVA-2026 is a prospective, randomized clinical study evaluating whether ultrasound-guided peripheral vascular access improves first-attempt cannulation success compared with conventional landmark…
- Conditions
- Peripheral Venous Catheterization, Difficult Intravenous Access, Catheterization, Peripheral
- Trial name
- TVA-2026 (NCT07798427)
- Testing
- Ultrasound-Guided Peripheral Vascular Access, Standard Peripheral Vascular Access, Point-of-Care Ultrasound System for Vascular Access Guidance
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Truway Health, Inc.
Carcinoma, Non-small-cell Lung
Iressa Expanded Access Program (EAP)
A program for patients with non small cell lung cancer who may benefit from Iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.
- Conditions
- Carcinoma, Non-small-cell Lung, Metastases, Neoplasm
- Trial name
- NCT00034879
- Testing
- ZD1839 (Gefitinib)
- Where
- 626 sites in United States
- Sponsor
- AstraZeneca
Colorectal Cancer
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared…
- Trial name
- AndroMETa-CRC (NCT07525206)
- Testing
- Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil
- Where
- 88 sites in United States, Belgium and 8 more
- Volunteers
- 990 people
- Sponsor
- AbbVie